<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692159</url>
  </required_header>
  <id_info>
    <org_study_id>102ST101</org_study_id>
    <nct_id>NCT00692159</nct_id>
  </id_info>
  <brief_title>Study of TRC102 in Combination With Pemetrexed in Cancer Patients</brief_title>
  <official_title>Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to evaluate the safety and tolerability of TRC102 in
      combination with Alimta. In addition to safety, this study will also evaluate
      pharmacokinetics and tumor response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being performed to evaluate the safety and tolerability of TRC102 in
      combination with Alimta. In addition to safety, this study will also evaluate
      pharmacokinetics and tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable.</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics, assess anti-tumor activity, and assess pharmacodynamics</measure>
    <time_frame>Study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC102 + pemetrexed</intervention_name>
    <description>Oral TRC102 solution + IV pemetrexed</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has given informed consent

          -  The patient is willing and able to abide by the protocol

          -  The patient has cancer and curative therapy is unavailable or standard therapy has
             failed

          -  The patient is at least 18 years of age

          -  The patient has adequate ability to perform activities of daily living

          -  The patient has recovered from significant toxicities of previous therapy

          -  The patient has adequate organ function as assessed by laboratory testing

        Exclusion Criteria:

          -  The patient has had prior treatment with high-dose chemotherapy requiring stem cell
             rescue

          -  The patient is currently on treatment on another therapeutic clinical trial or has
             received an investigational drug within 4 weeks prior to first dose on this study

          -  The patient has had prior surgery, radiation or systemic therapy within 4 weeks of
             starting the study

          -  The patient has a history of CNS cancer

          -  The patient has an unstable medical condition including (not limited to) cardiac
             disease, HIV/AIDS, history of stroke, hepatitis or significant paricardial, pleural or
             peritoneal effusion

          -  The patient is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Leigh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tracon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.traconpharma.com</url>
    <description>TRACON Pharmaceuticals Inc. Web Site</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bryan Leigh, MD, Medical Monitor</name_title>
    <organization>TRACON Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>TRC102</keyword>
  <keyword>Methoxyamine HCL</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Alimta</keyword>
  <keyword>Tracon</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Cancer</keyword>
  <keyword>BER</keyword>
  <keyword>Base Excision Repair</keyword>
  <keyword>Small Molecule</keyword>
  <keyword>Anti-folate</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Neoplastic Processes</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Pathological Conditions, Signs and Symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

